Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Classement en actions #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Prix de l'action
$0.1502
Dernière synchronisation: 2024-11-04
Capitalisation boursière
$6.43M
Changement (1 jour)
-5.45%
Changement (1 an)
0.00%
Pays
US
Échange Renalytix Plc (RNLX)

Catégorie

Healthcare
Ratio P/S pour Renalytix Plc (RNLX)
Ratio P/S au August 2026 TTM : 9.85
Selon les derniers rapports financiers et le cours de l'action de Renalytix Plc, le ratio cours/ventes actuel (TTM) est 9.85. À la fin de 2023, le ratio P/S était de 35.27.
Historique du ratio P/S pour Renalytix Plc de 2018 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 9.85 66.11%
2024 5.93 -83.19%
2023 35.27 25.79%
2022 28.04 -96.18%
2021 733.39 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
1.64 -83.31%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
77.67 688.51%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
0.84 -91.45%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
6.37 -35.29%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
- -
US